GENELUX Corp
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on the signature page hereto)
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Thomas Zindrick, J.D. and Lourie Zak, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Thomas Zindrick | President, Chief Executive Officer and Chairman (Principal Executive and Financial Officer) | March 29, 2024 |
| Thomas Zindrick, J.D. | ||
| /s/ Lourie Zak | Chief Financial Officer (Principal Accounting Officer) | March 29, 2024 |
| Lourie Zak | ||
| /s/ Mary Mirabelli | Director | March 29, 2024 |
| Mary Mirabelli | ||
| /s/ James L. Tyree | Director | March 29, 2024 |
| James L. Tyree | ||
| /s/ John Thomas | Director | March 29, 2024 |
| John Thomas, Ph.D. | ||
| /s/ John Smither | Director | March 29, 2024 |
| John Smither | ||
Genelux Corporation
Index to the Financial Statements
For the Years Ended December 31, 2023 and 2022
| Report of Independent Registered Public Accounting Firm (PCAOB ID 572) | F-2 |
|---|---|
| Balance Sheets at December 31, 2023 and 2022 | F-3 |
| Statements of Operations for the Years Ended December 31, 2023 and 2022 | F-4 |
| Statements of Comprehensive Loss for the Years Ended December 31, 2023 and 2022 | F-5 |
| Statements of Shareholders’ Equity (Deficit) for the Years Ended December 31, 2023 and 2022 | F-6 |
| Statements of Cash Flows for the Years Ended December 31, 2023 and 2022 | F-7 |
| Notes to the Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.